1 week Ago By ABMN Staff
Orion Portfolio Solutions LLC decreased its holdings in Xenon Pharmaceuticals Inc. ( NASDAQ:XENE – Free Report ) by 7.4% in the 4th quarter, Holdings Channel.
com reports. The firm owned 13,436 shares of the biopharmaceutical company’s stock after selling 1,067 shares during the period. Orion Portfolio Solutions LLC’s holdings in Xenon Pharmaceuticals were worth $527,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its stake in Xenon Pharmaceuticals by 1,263.
2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after buying an additional 905,129 shares in the last quarter.
Jennison Associates LLC grew its position in shares of Xenon Pharmaceuticals by 39.0% in the fourth quarter. Jennison Associates LLC now owns 801,553 shares of the biopharmaceutical company’s stock valued at $31,421,000 after purchasing an additional 224,892 shares in the last quarter.
TimesSquare Capital Management LLC raised its stake in shares of Xenon Pharmaceuticals by 9.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 848,850 shares of the biopharmaceutical company’s stock valued at $33,275,000 after purchasing an additional 70,557 shares during the period.
Two Sigma Advisers LP lifted its holdings in Xenon Pharmaceuticals by 31.0% during the 3rd quarter. Two Sigma Advisers LP now owns 273,700 shares of the biopharmaceutical company’s stock worth $10,776,000 after purchasing an additional 64,800 shares in the last quarter.
Finally, BIT Capital GmbH bought a new position in Xenon Pharmaceuticals in the 4th quarter worth about $2,114,000. Institutional investors own 95.45% of the company’s stock.
Analysts Set New Price Targets Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th.
Royal Bank of Canada reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. StockNews.com downgraded shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday.
William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating and a $67.
00 price objective for the company. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $57.
38. Insiders Place Their Bets In other news, CEO Ian Mortimer sold 16,315 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.
50, for a total transaction of $660,757.50. Following the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at approximately $1,267,731.
This trade represents a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink .
Insiders own 5.52% of the company’s stock. Xenon Pharmaceuticals Stock Up 4.
2 % XENE opened at $30.63 on Tuesday. The business’s fifty day simple moving average is $36.
71 and its 200 day simple moving average is $39.35. Xenon Pharmaceuticals Inc.
has a 52 week low of $27.56 and a 52 week high of $46.00.
The stock has a market cap of $2.34 billion, a PE ratio of -10.86 and a beta of 1.
21. Xenon Pharmaceuticals ( NASDAQ:XENE – Get Free Report ) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.
84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05.
As a group, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.
Xenon Pharmaceuticals Profile ( Free Report ) Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. Featured Articles Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. ( NASDAQ:XENE – Free Report ). Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
